The Prognostic Value of Blood Glucose Level on Admission in Non-diabetic Patients with Acute Myocardial Infarction

Overview

Journal J Med Life

Specialty General Medicine

Date 2010 Feb 2

PMID 20112471

Citations 1

Authors

V Chioncel

D Mincu

M Anastasiu

C Sinescu

Affiliations

Soon will be listed here.

Abstract

Unlabelled: The diabetic patients represent a population with a high risk of morbidity and mortality because of vascular complications. Out of them, all the patients with acute ST-elevation myocardial infarction have a more reserved prognostic than those without diabetes mellitus. Moreover, the patients with impaired glucose tolerance have a more severe evolution in case of a myocardial infarction.

Aim: We wondered about the progress of patients with myocardial infarction and high blood glucose levels in admittance who had not been previously diagnosed with diabetes mellitus.

Materials And Methods: We took 128 patients (who did not have diabetes) with acute ST-elevation myocardial infarction and divided them into three groups, according to the blood glucose level in admittance (<140 mg/dL, 140-200 mg/dL and > 200 mg/dL); we also analyzed a group of diabetics with acute myocardial infarction who were admitted in the same period in our clinic. We made a prospective analysis over a period of 30 days. We evaluated the mortality at 30 days (as primary objective), as well as the extent of the infarction and the change of the left ventricle systolic function (secondary objectives).

Results: Both mortality and the mass of myocardial necrosis grew relative to the blood glucose level in admittance; instead, the ejection fraction varied inversely to the initial blood glucose level.

Conclusion: The admittance blood glucose level represents a useful and available marker for the initial stratification of risks in patients with acute myocardial infarction, even in those undiagnosed with diabetes mellitus.

Citing Articles

Stress hyperglycemia and poor outcomes in patients with ST-elevation myocardial infarction: a systematic review and meta-analysis.

Alkatiri A, Qalby N, Mappangara I, Zainal A, Cramer M, Doevendans P Front Cardiovasc Med. 2024; 11:1303685.

PMID: 38529334 PMC: 10961461. DOI: 10.3389/fcvm.2024.1303685.

References

Wahab N, Cowden E, Pearce N, Gardner M, Merry H, Cox J . Is blood glucose an independent predictor of mortality in acute myocardial infarction in the thrombolytic era?. J Am Coll Cardiol. 2002; 40(10):1748-54. DOI: 10.1016/s0735-1097(02)02483-x. View

Grundy S, Benjamin I, Burke G, Chait A, Eckel R, Howard B . Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation. 1999; 100(10):1134-46. DOI: 10.1161/01.cir.100.10.1134. View

Pandolfi A, Cetrullo D, Polishuck R, Alberta M, Calafiore A, Pellegrini G . Plasminogen activator inhibitor type 1 is increased in the arterial wall of type II diabetic subjects. Arterioscler Thromb Vasc Biol. 2001; 21(8):1378-82. DOI: 10.1161/hq0801.093667. View

De Feo P, Gaisano M, Haymond M . Differential effects of insulin deficiency on albumin and fibrinogen synthesis in humans. J Clin Invest. 1991; 88(3):833-40. PMC: 295469. DOI: 10.1172/JCI115384. View

Malmberg K, Ryden L, Wedel H, Birkeland K, Bootsma A, Dickstein K . Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J. 2005; 26(7):650-61. DOI: 10.1093/eurheartj/ehi199. View

Kannel W, DAgostino R, Wilson P, Belanger A, Gagnon D . Diabetes, fibrinogen, and risk of cardiovascular disease: the Framingham experience. Am Heart J. 1990; 120(3):672-6. DOI: 10.1016/0002-8703(90)90026-t. View

Foo K, Cooper J, Deaner A, Knight C, Suliman A, Ranjadayalan K . A single serum glucose measurement predicts adverse outcomes across the whole range of acute coronary syndromes. Heart. 2003; 89(5):512-6. PMC: 1767629. DOI: 10.1136/heart.89.5.512. View

Malmberg K, Norhammar A, Wedel H, Ryden L . Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: long-term results from the Diabetes and Insulin-Glucose Infusion in Acute Myocardial.... Circulation. 1999; 99(20):2626-32. DOI: 10.1161/01.cir.99.20.2626. View

Norhammar A, Malmberg K, Ryden L, Tornvall P, Stenestrand U, Wallentin L . Under utilisation of evidence-based treatment partially explains for the unfavourable prognosis in diabetic patients with acute myocardial infarction. Eur Heart J. 2003; 24(9):838-44. DOI: 10.1016/s0195-668x(02)00828-x. View

10.

Malmberg K, Ryden L, Efendic S, Herlitz J, Nicol P, Waldenstrom A . Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol. 1995; 26(1):57-65. DOI: 10.1016/0735-1097(95)00126-k. View

11.

Sack M, Yellon D . Insulin therapy as an adjunct to reperfusion after acute coronary ischemia: a proposed direct myocardial cell survival effect independent of metabolic modulation. J Am Coll Cardiol. 2003; 41(8):1404-7. DOI: 10.1016/s0735-1097(03)00164-5. View

12.

Colwell J, Nesto R . The platelet in diabetes: focus on prevention of ischemic events. Diabetes Care. 2003; 26(7):2181-8. DOI: 10.2337/diacare.26.7.2181. View

13.

Ganda O, Arkin C . Hyperfibrinogenemia. An important risk factor for vascular complications in diabetes. Diabetes Care. 1992; 15(10):1245-50. DOI: 10.2337/diacare.15.10.1245. View

14.

Apstein C . The benefits of glucose-insulin-potassium for acute myocardial infarction (and some concerns). J Am Coll Cardiol. 2003; 42(5):792-5. DOI: 10.1016/s0735-1097(03)00844-1. View

15.

Ishihara M, Kojima S, Sakamoto T, Asada Y, Tei C, Kimura K . Acute hyperglycemia is associated with adverse outcome after acute myocardial infarction in the coronary intervention era. Am Heart J. 2005; 150(4):814-20. DOI: 10.1016/j.ahj.2004.12.020. View

16.

Zeller M, Steg P, Ravisy J, Laurent Y, Janin-Manificat L, LHuillier I . Prevalence and impact of metabolic syndrome on hospital outcomes in acute myocardial infarction. Arch Intern Med. 2005; 165(10):1192-8. DOI: 10.1001/archinte.165.10.1192. View

17.

Stehouwer C, Nauta J, Zeldenrust G, HACKENG W, Donker A, den Ottolander G . Urinary albumin excretion, cardiovascular disease, and endothelial dysfunction in non-insulin-dependent diabetes mellitus. Lancet. 1992; 340(8815):319-23. DOI: 10.1016/0140-6736(92)91401-s. View

18.

Meier J, Deifuss S, Klamann A, Launhardt V, Schmiegel W, Nauck M . Plasma glucose at hospital admission and previous metabolic control determine myocardial infarct size and survival in patients with and without type 2 diabetes: the Langendreer Myocardial Infarction and Blood Glucose in Diabetic Patients Assessment.... Diabetes Care. 2005; 28(10):2551-3. DOI: 10.2337/diacare.28.10.2551. View

19.

Brunner E, Shipley M, Witte D, Fuller J, Marmot M . Relation between blood glucose and coronary mortality over 33 years in the Whitehall Study. Diabetes Care. 2005; 29(1):26-31. DOI: 10.2337/diacare.29.01.06.dc05-1405. View

20.

Cardillo C, Campia U, Bryant M, Panza J . Increased activity of endogenous endothelin in patients with type II diabetes mellitus. Circulation. 2002; 106(14):1783-7. DOI: 10.1161/01.cir.0000032260.01569.64. View